Paradigm Biopharmaceuticals Ltd has released a press release.
Preliminary Results from Phase 2 MPS I Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
- Paradigm cleared for phase 3 trial by US FDA
- Phase 2 Synovial Fluid Biomarker Study Update
- Positive top-line results from preclinical study in ards
- First mps-vi patient dosed under phase 2 trial in Brazil
Later from Paradigm Biopharmaceuticals
- PAR reports postive topline results in heart failure model
- Paradigm treats first subjects in phase 3 trial of zilosul
- Paradigm 1HY22 Key Activity Highlights
- S&P DJI Announces March 2022 Quarterly Rebalance
- Clarification of recent analyst report on Patent Protection
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals